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Abstract
Rationale—Phosphodiesterase-4 (PDE4) and neuroimmune signaling have been posited to 
regulate alcohol drinking.
Objectives—This study evaluated the involvement of PDE4 and Il22ra2 on ethanol (EtOH) 
intake by alcohol-preferring (P) and high-alcohol drinking (HAD1) rats.
Methods—Exp 1 determined the dose-response effects of PDE4 inhibitors, rolipram and Ro 
20-1724, on 2h/day free-choice EtOH intake by adult P and HAD1 rats. Exps 2–3 examined the 
effects of repeated administration with the PDE4 inhibitors on EtOH or sucrose intake, and 
locomotor behavior. Exp 4 determined Pde4-associated gene expression differences in subregions 
of the extended amygdala, between high- and low-alcohol-consuming rat lines. Exp 5 evaluated 
the effects of infusing short hairpin RNA to knock down Il22ra2 in the nucleus accumbens (NAc) 
shell on 24h free-choice EtOH drinking by P rats.
Results—Administration of rolipram or Ro 20-1724 reduced EtOH intake by P rats; Ro 20-1724 
reduced EtOH intake by HAD1 rats. Repeated rolipram or Ro 20-1724 exposure reduced EtOH 
intake by P and HAD1 rats. PDE4 inhibition induced motor impairment during the first hour of 
EtOH intake by P rats. Higher gene expression levels for PDE4A were found in the NAc shell of P 
vs. NP rats. ShRNAs targeting Il22ra2 in the NAc shell significantly reduced chronic EtOH intake.
Conclusions—PDE4 and neuroinflammatory/immune signaling pathways could represent 
molecular targets for the treatment of alcohol use disorders, in genetically predisposed subjects. 
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This study underscores the importance of testing compounds over multiple days and rat lines when 
determining efficacy to disrupt excessive alcohol intake.
Keywords
Alcohol-preference; animal model; genetic predisposition; high-alcohol consuming; selective 
breeding; Interleukin 22 receptor
Introduction
Evidence suggests that 3’,5’-cyclic adenosine monophosphate (cAMP) reduces activity of 
pro-inflammatory cytokines, such as tumor necrosis factor α (TNF- α) and interleukin 
(IL)-17, and increases activity of anti-inflammatory mediators such as IL-10 (Baumer et al. 
2007). Thus, cAMP regulates homeostasis in immune cell signaling (Oger et al. 2005). One 
manner of modulating cAMP, is through the enzymatic activity of 3’,5’-cyclic nucleotide 
phosphodiesterase type-IV (PDE4; Conti and Beavo 2007; Houslay and Adams 2003). 
PDE4 can interrupt the homeostatic immune process via its action on cAMP, altering the 
balance of pro- and anti-inflammatory mediators (Oger et al. 2005).
Alterations in cAMP and neuroimmune signaling are associated with elevated reward and 
reinforcement from drugs of abuse including cocaine, morphine, methamphetamine and 
alcohol (Boudreau et al. 2009; Hutchinson et al. 2007; Janes et al. 2009; Misra and Pandey 
2006; Snider et al. 2013; Terwilliger et al. 1991; Thiele et al. 2000). Genetic differences 
(alcohol-preferring [P] vs –nonpreferring [NP] rats) in cAMP second messenger systems are 
associated with differences in a propensity for alcohol abuse (Pandey et al. 1999). Similarly, 
chronic alcohol drinking reduces cellular cAMP levels (Gobejishvili et al. 2008) and 
increases immune signaling and inflammatory response (Fernandez-Lizarbe et al. 2009; 
Gobejishvili et al. 2008; Hu et al. 2013; Qin et al. 2008). Alcohol and drug dependence are 
associated with complex interactions between immune and neural signaling, stress-
associated activity (e.g. hypothalamic-pituitary-adrenal axis), and transcription activity 
within reward neurocircuitry (Allen et al. 2011; Crews and Nixon 2009; Crews et al. 2011; 
Frank et al. 2011; Kelley and Dantzer, 2011; Misra and Pandey 2006; Rosi, 2011; 
Yakovleva et al. 2011).
Innate differences in expression of genes involved in apoptosis and cell death, as well as 
inflammation, including Il22ra2, have been reported in the shell region of the nucleus 
accumbens (NAc) and in the ventral tegmental area (VTA) of some high alcohol-preferring 
rat lines (e.g. P and High Alcohol Drinking [HAD1 and HAD2] rats), relative to their non-
alcohol-preferring counterparts (e.g. NP and Low Alcohol Drinking [LAD1 and LAD2] rats; 
McBride et al. 2013b). Il22ra2 encodes for IL-22 receptor α2 subunit (IL-22ra2; IL-22BP; 
CFR2–10), which is primarily a pro-inflammatory antagonist of IL-22 activity (Kotenko et 
al. 2001). Similarly, changes in expression of genes associated with cell death have been 
reported in the NAc shell of P rats following binge-like alcohol drinking (McBride et al. 
2010, 2013a), and in the VTA of P rats following excessive binge-like alcohol drinking 
(McBride et al. 2013a). These findings may indicate that innate vulnerability to 
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neuroinflammation is exacerbated by excessive ethanol (EtOH) intake, and could contribute 
to this high alcohol drinking phenotype.
PDE4 isoforms A, B and D are the primary mediators of cAMP activity in inflammatory 
cells (Page and Spina 2011). Evidence suggests that PDE4B may be a target of interest for 
addiction research, due to its high expression levels in brain regions associated with reward 
and reinforcement (e.g. NAc and central nucleus of the amygdala [CeA]; Cherry and Davis 
1999; Perez-Torres et al. 2000). PDE4B expression is up-regulated following chronic 
alcohol exposure in vitro (Gobejishvili et al. 2008) and is heavily involved in inflammatory 
processes (cf. Jin et al. 2012) which are implicated in alcohol and drug dependence (Crews 
et al. 2011).
A recent study indicated that the non-selective PDE inhibitor ibudilast (AV-411) reduced 2h 
EtOH intake by P and HAD1 rats, as well as alcohol-dependent C57BL/6J mice (Bell et al. 
2014a). In addition, rolipram, a selective inhibitor of PDE4 (Kenk et al. 2011), reduced 
EtOH-reinforced operant responding by Fawn-Hooded rats, without altering sucrose-
reinforced responding (Wen et al. 2012). Similarly, rolipram and another PDE4 inhibitor Ro 
20-1724 (Wachtel 1983) reduced 2-bottle choice EtOH intake in C57BL/6J mice (Hu et al. 
2011).
The current study examined the effects of selective PDE4 inhibitors on binge EtOH intake, 
by P and HAD1 rats. Innate Pde4 gene expression differences between P vs NP and HAD1 
vs LAD1 rats were also determined. Finally, the effects of microinfusing shRNAs for 
Il22ra2 in the NAc shell on alcohol drinking by P rats were evaluated.
Materials and Methods
Subjects
The subjects were adult, male P, NP, HAD1, and LAD1 rats and female P rats. EtOH-naïve 
animals were pair-housed in standard plastic tubs. Subjects given EtOH access were housed 
individually in hanging stainless steel wire-mesh cages (containing a Plexiglas platform). 
All rats received free access to standard laboratory chow and water. Male rats used for 2h 
scheduled access drinking were maintained on a 12/12h reverse light cycle (lights off at 
1030). Female P rats used for shRNA experiments, were given 24h free-choice access to 
EtOH and were maintained on a 12/12h normal light cycle (lights on at 0700). Subjects were 
housed in a temperature- (21°C) and humidity- (50%) controlled vivarium. Animals were 
maintained in facilities accredited by the Association for the Assessment and Accreditation 
of Laboratory Animal Care. All experimental procedures were approved by the Institutional 
Animal Care and Use Committees of the Indiana University Schools of Dentistry and 
Medicine (Indianapolis, IN) and are in accordance with the guidelines of the Institutional 
Animal Care and Use Committee of the National Institute on Drug Abuse, National 
Institutes of Health, and the Guide for the Care and Use of Laboratory Animals (Research 
Institute for Laboratory Animal Research 2011).
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Procedures
In Exps 1 and 2, the effects of PDE4 inhibitors rolipram (Sigma-Aldrich, St. Louis, MO, 
USA) and Ro 20-1724 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) on EtOH intake 
by male P and HAD1 rats were examined during 2-hr, 3-bottle (water, and 15% and 30% 
EtOH) free-choice test sessions. The length of the EtOH access period was titrated as 
follows: two weeks of 24h access; two weeks of 4h access; then two weeks of 2h access. On 
the final day of access, one cohort (n = 10/rat line) was assessed for EtOH intake (g/kg) and 
blood EtOH concentration (BEC) 30 min into the EtOH drinking session. Briefly, animals 
were killed with CO2 inhalation, and then decapitated to collect blood from the trunk cavity. 
Blood samples were centrifuged, serum was extracted, frozen on dry ice, and stored at 
−80°C for subsequent analysis of BEC (Analox Instruments, Ltd., Lunenburg, MA, USA).
Dose-dependent effects of PDE4 inhibition on EtOH intake—Two cohorts of rats 
were randomly assigned to treatment groups balanced for equivalent EtOH intake. For Exp 1 
(within subject dose-response effects), each P and HAD1 male rat (n = 16/rat line) was 
administered four doses of either rolipram (0, 0.25, 0.50, and 1.00 mg/kg; i.p.) or Ro 
20-1724 (0, 5, 10, and 20 mg/kg, i.p.) in a counterbalanced design across 4 consecutive 
days. These doses were selected to approximate those previously reported to reduce alcohol 
drinking in mice (Hu et al. 2011). The vehicle for all compounds was a few drops of Tween 
80 in sterile saline.
Effects of repeated PDE4 inhibition on EtOH or sucrose intake—For Exp 2, P 
and HAD1 rats were given a single dose of one of the PDE4 inhibitors, or vehicle for 5 
consecutive days. Rolipram was administered at a dose of 1 mg/kg in P and HAD1 rats (n = 
8/rat line). Ro 20-1724 was administered at 10 (n = 9) or 20 (n = 6) mg/kg in P rats and 20 
mg/kg in HAD1 rats (n = 8). Next, EtOH was withdrawn for 2 weeks; then rats were given 
two weeks (Mon-Fri, weekends off) of 2h access to 2% w/v sucrose. The following week 
served to assess sucrose intake, during which the rats received rolipram or Ro 20-1724. All 
compounds were administered i.p. 60 min prior to the drinking test sessions, which 
coincided with the beginning of the dark cycle. Before and after each test session, EtOH or 
sucrose and water intakes were assessed. Body weight was measured at least 3 days a week.
Locomotor response to repeated PDE4 inhibition—A separate cohort of male P and 
HAD1 rats (n = 7/drug/rat line) was tested for time-dependent effects of repeated exposure 
to the PDE4 inhibitors on locomotor activity (LMA) (Exp 3). Rats were provided the same 
EtOH drinking protocol as described above, followed by a 4-wk alcohol abstinence period. 
After this, subjects were injected with 1 mg/kg rolipram or 20 mg/kg Ro 20-1724, or vehicle 
across 5 consecutive days. On the 5th injection day, rats were placed in LMA monitoring 
chambers for 30 min trials starting at 60 or 120 min post-injection. These time periods 
reflect the beginning of the first and second hour of EtOH or sucrose access in Exps 1 and 2. 
Ambulatory activity and rearing were recorded (Versadat v. 3.02-127E, Accusan 
Instruments Inc., Columbus, OH). Food and 24h water consumption as well as body weight 
were measured daily, immediately prior to the start of the dark cycle, but were not available 
during the LMA test sessions.
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Pde4 gene expression in the NAc shell, CeA, and VTA—Pde4 gene expression in 
the NAc shell, CeA and VTA was assessed in EtOH-naïve male P, NP, HAD1 and LAD1 
rats (Exp 4). Microarray procedures to assess levels of gene expression in micro-punched 
brain regions were conducted as previously described (McBride et al. 2013b). CEL files 
were imported into Partek Genomics Suite (Partek, Inc., St. Louis, MO) for analysis.
Effects of shRNA for Il22ra2 in the NAc shell on EtOH intake of P rats—To 
examine a possible role for neuroimmune signaling in alcohol drinking (Exp 5), two 
lentiviral vector constructs (#1928, #1408) targeting Il22ra2 mRNA for knockdown in the 
NAc shell of adult female P rats were synthesized by the Lasek lab (University of Illinois, 
Chicago, IL). Sequences encoding shRNAs targeting Il22ra2 were designed and cloned into 
the lentiviral vector pLL3.7 and lentivirus was produced as previously described (Lasek et 
al. 2007). The 19 nucleotide targeting sequences for Il22ra2 were as follows: 
shIl22ra2-1408: 5’-GTGGCTGTCTCTAAATTAA-3’; shIl22ra2-1928: 5’-
GGTGCTCCAACGTATTACT-3’. Rats were given continuous (24h), free-choice access to 
EtOH (15% v/v) for at least 6 weeks prior to surgery to stabilize EtOH drinking levels, then 
were balanced into two groups with equivalent EtOH drinking levels. Stereotaxic surgeries 
were performed on the rats under isoflurane anesthesia; each animal received bilateral 
infusions aimed at the NAc shell (AP +1.7, ML +2.4, DV −7.5, 10 ° offset from vertical; 
Paxinos and Watson, 1998). Animals were infused with 1.5 µl/side of lentivirus expressing 
Il22ra2 shRNA or a scrambled vector control (n = 7–9/group), at a flow rate of 0.2 µl/min. 
The infusate was allowed 10 min to diffuse. Incision sites were closed with stainless steel 
wound clips. Three days post-infusion, rats were given 24h free-choice access to 15% EtOH 
and water for 6–7 weeks. EtOH (g/kg) and water (ml/kg) intakes were assessed daily. Body 
weights were measured 3 days/wk. Next, EtOH access was withdrawn, and rats were given 2 
weeks with 24h access to 2% w/v sucrose.
Data analyses and statistics—Fluid intakes were determined as before and after 
changes in the weight of glass drinking bottles. EtOH intake was converted to g of absolute 
EtOH consumed/kg of body weight/unit time. BECs were assessed in triplicate on the 
Analox alcohol analyzer and averaged. Linear regression analyses were used to assess the 
association between EtOH intake during the first 30 min of access and BECs.
For Exp 1, omnibus three-way (line x dose x day) mixed-model ANOVAs with repeated 
measures for day were used to assess 2h EtOH intake. Next, the two rat lines were analyzed 
separately, using two-way (dose x day) ANOVAs with repeated measures for day, to assess 
dose-dependent changes in EtOH and water intake and body weight during the post-
treatment test periods. If a significant interaction term or overall dose effect was obtained, 
one-way ANOVAs, followed by Dunnett’s multiple comparisons t-tests, were conducted for 
each dose over the treatment period for 2h EtOH or water intake, 24h water and food intake, 
and body weight, to determine significant individual dose effects compared to vehicle. For 
Exp 2, separate two-way (treatment × day) ANOVAs with repeated measures for day, 
followed by one-way ANOVAs (P rats) or independent samples t-tests (HAD1 rats) were 
used to assess 2h EtOH or sucrose intake, 24h water and food intake, and body weight. For 
Exp 3, one-way ANOVAs were used to analyze the effect of treatment and treatment-test 
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interval (i.e. 60–90 or 120–150 min; “time”) on cumulative distance traveled and rearing 
counts over the 30 min test sessions for each rat line separately. Dunnett’s multiple 
comparisons t-tests were used to compare behavior of PDE4 inhibitor-exposed groups to 
vehicle-values at the two post-exposure time-points.
PDE4 gene expression levels in the NAc, CeA, and VTA of P vs. NP and HAD1 vs. LAD1 
rats (Exp 4) were analyzed as previously reported (McBride et al. 2013b). Robust multichip 
average (RMA; Bolstad, 2003) expression levels were generated for all probe sets using the 
RMA background correction, Quantile normalization and summarization by Median Polish. 
Summarized signals for each probe set were log2 transformed. Student’s t-tests were 
performed between each line-pair (P/NP, HAD1/LAD1) using log2 transformed signals. 
Fold-changes were calculated using raw expression levels.
To assess the effects of shRNAs targeting Il22ra2 on EtOH intake (Exp 5), EtOH intake was 
averaged by week. Two-way (treatment x week) ANOVAs with repeated measures for week 
were used to assess 24h EtOH or sucrose or water intake, as well as body weight. If a 
significant interaction term or overall treatment effect was obtained, then independent 
samples t-tests were conducted on each treatment week and over the treatment period for 
24h EtOH or sucrose intake, 24h water intake, and body weight.
Results
BEC (30 min)
For P rats, the average EtOH intake during the first 30 min of access was 1.7 ± 0.2 g/kg, and 
the average 30-min BEC was 80 ± 12 mg%. For HAD1 rats, the average EtOH intake during 
the first 30 min of access was 2.3 ± 0.2 g/kg, and the average BEC was 50 ± 12 mg%. 
Linear regression analyses revealed significant associations between EtOH intake and BEC 
in both rat lines [F’s (1,9) ≥ 6.63, p’s < 0.05].
Dose-dependent effects of PDE4 inhibition on EtOH intake
The omnibus mixed-model ANOVA in P and HAD1 rats revealed a significant main effect 
of dose [F(3,82) = 5.19, p < 0.01] of rolipram (Fig. 1a). Separate two-way ANOVAs 
revealed a significant main effect of dose in P rats [F(3,45) = 7.18, p < 0.001]. The 
univariate ANOVA, followed by Dunnett’s multiple comparisons t-tests, revealed that 1 
mg/kg rolipram reduced (~40%) 2h EtOH intake in P rats, relative to vehicle (p < 0.001). 
For HAD1 rats, rolipram did not alter 2h EtOH intake significantly, relative to vehicle, 
although there was a trend toward a reduction.
The omnibus mixed-model ANOVA in P and HAD1 rats revealed significant line by dose 
[F(3,82) = 2.77, p = 0.047] and dose by day [F(9,58) = 3.12, p = 0.004] interactions, as well 
as significant main effects of line and dose [F’s (1–3,82) ≥ 16.4, p’s < 0.001]for Ro 20-1724 
(Fig. 1b). Separate two-way ANOVAs revealed significant main effects of dose in P and 
HAD1 rats [F’s (3,38) ≥ 11.0, p’s < 0.001]. One-way ANOVAs, followed by Dunnett’s t-
tests, revealed that all Ro 20-1724 doses reduced (~45%) 2h EtOH intake by P rats, and 20 
mg/kg Ro 20-1724 reduced (~40%) 2h EtOH intake by HAD1 rats (p’s < 0.001).
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Effects of repeated PDE4 inhibition on EtOH or sucrose intake
In Exp 2, following repeated administration of 1.0 mg/kg rolipram (Figs. 2a, b), an omnibus 
ANOVA revealed a significant main effect of treatment [F(1,14) = 36.2, p < 0.001]. 
Separate two-way ANOVAs revealed significant main effects of treatment in P and HAD1 
rats [F’s(1,14) ≥ 10.2, p’s ≤ 0.01]. Independent samples t-tests revealed that 1 mg/kg 
rolipram reduced 2h EtOH intake in HAD1 and P rats (~30–40%, respectively) on all test 
days, with the exception of Day 5 in HAD1 rats, as well as over the 5-day test period [t’s 
(14) ≥ 2.24, p’s < 0.05]. For Ro 20-1724, in P rats (Fig. 2c) the two-way ANOVA revealed a 
significant dose by day interaction [F(8,88) = 3.79, p = 0.001], as well as a significant main 
effect of dose [F(2,22)= 15.9, p < 0.001]. Individual one-way ANOVAs for each test day 
revealed that 10 and 20 mg/kg Ro 20-1724 reduced EtOH intake on the first day. The 20 
mg/kg dose also reduced (~50%) EtOH intake by P rats on the 2nd, 3rd, and 4th days, and 
over the 5-day period (p’s ≤ 0.01). For HAD1 rats (Fig. 2d), the two-way ANOVA revealed 
a significant main effect of treatment [F(1,14) = 10.1, p < 0.01]. Independent-samples t-tests 
for each test day revealed that 20 mg/kg Ro 20-1724 reduced (~30%) EtOH intake on the 
1st, 2nd, 3rd and 5th days, as well as over the 5-day period (p’s < 0.05).
An omnibus three-way ANOVA revealed a significant treatment by day interaction 
[F(4,112) = 12.0, p < 0.001], and a significant main effect of line [F(1,28) = 22.8, p < 0.001] 
on the effect of rolipram on sucrose intake (Figs. 3a, b). Separate two-way ANOVAs 
revealed significant treatment by day interactions for both rat lines [F’s (4,56) ≥ 5.39, p’s < 
0.001]. Independent samples t-tests revealed that rolipram treatment reduced 2h sucrose 
intake on the 1st test day [t’s (14) ≥ 2.61; p’s < 0.05], and increased sucrose intake on the 4th 
test day [t’s (14) ≥ 2.29; p’s < 0.05] in both rat lines, relative to vehicle. Rolipram did not 
alter sucrose intake over the 5-day test period in either rat line. For Ro 20-1724effects on 
sucrose intake, for P rats (Fig. 3c), the two-way ANOVA revealed a significant treatment by 
day interaction [F(8,84) = 3.07, p < 0.01]. Individual one-way ANOVAs for each day 
revealed that 10 and 20 mg/kg Ro 20-1724 reduced sucrose drinking on the first day (p’s < 
0.05), but did not alter sucrose intake across the 5-day test period. Ro 20-1724 did not alter 
sucrose intake of HAD1 rats (Fig. 3d).
In Exp 1, HAD1 rats given 1 mg/kg rolipram were the only animals to exhibit changes 
(~30% increase) in 24h water intake. No other groups treated with the PDE4 inhibitors 
differed from vehicle in water or food intake, or body weights (Tables 1 and 2). Following 
repeated exposure, rolipram increased 24h water intake in P rats. Ro 20-1724 (20 mg/kg) 
reduced water drinking by P rats, while increasing water intake by HAD1 rats (Table 3).
Locomotor response to repeated PDE4 inhibition
During LMA testing (Fig. 4), P rats displayed reductions in motor activity following 
repeated administration with the PDE4 inhibitors. In P rats, two-way ANOVAs assessing 
total distance travelled revealed a significant time by treatment interaction [F(4,18) = 3.03, p 
< 0.05] and main effect of treatment [F(2,18) = 6.50, p < 0.01]. Rolipram and Ro 20-1724 
reduced ambulatory behavior by P rats at 60–90, but not 120–150, min post-injection, which 
corresponds to the first 30 min of EtOH or sucrose access periods, relative to vehicle (p < 
0.05; Fig. 4a). For total rearing counts, two-way ANOVAs revealed a significant main effect 
Franklin et al. Page 7
Psychopharmacology (Berl). Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
of treatment [F(2,18) = 17.2, p < 0.001]. Rearing was reduced in P rats at 60–90, but not 
120–150, min after Ro 20-1724, but not after rolipram, treatment (p < 0.05; Fig. 4c). PDE4 
inhibition did not alter LMA or rearing behavior in HAD1 rats (Fig. 4b, d).
PDE4 gene expression in the NAc shell, CeA, and VTA
Pde4 distribution was isoform-, line-, and site-specific (Table 4). In the NAc shell of P rats, 
Pde4a expression was higher and Pde4b expression was lower, relative to NP rats. In the 
CeA, Pde4b expression was also lower relative to NP rats. There were no significant 
differences between HAD1 and LAD1 rats in NAc shell or CeA Pde4 isoform expression. In 
the VTA, HAD1 rats displayed slightly higher Pde4b expression, relative to LAD1 rats. P 
and NP rats did not differ in VTA Pde4 isoform expression.
Effects of microinfusing shRNAs for Il22ra2 into the NAc shell on EtOH intake by P rats
Infusion of shRNA construct #1928 targeting Il22ra2 (shIl22ra2) in the NAc shell reduced 
(~35%) EtOH intake during the final 5 weeks of EtOH access compared to expression of a 
non-targeting control shRNA (shScr) (Fig. 5a). The two-way ANOVA revealed a significant 
treatment by week interaction [F(6,78) = 2.64, p < 0.05], as well as a significant main effect 
of treatment [F(1,13) = 6.51, p < 0.05]. Independent samples t-tests revealed that EtOH 
intake was reduced in Weeks 3–7, in subjects infused with shIl22ra2, relative to shScr [t’s 
(13) > 2.88; p’s < 0.05]. Similar results were obtained following the test of a second 
shIl22ra2 construct #1408, which reduced EtOH intake (~5.2 to ~3.7 g/kg/day) over the 
final 4 weeks of EtOH access ( p’s < 0.05). Neither shIll22ra2 construct reduced sucrose 
(Fig. 5b & 5d), water intakes (data not shown) or body weights (data not shown).
Discussion
The present study tested the hypothesis that inhibition of PDE4 would reduce 2h binge 
EtOH intake by P and HAD1 rats. In the dose-response experiment, both rolipram and Ro 
20-1724 appeared to be more effective in reducing 2h EtOH intake by P compared to HAD1 
rats (Figs. 1 and 2). Disparities in the effects of PDE4 inhibitors to alter EtOH drinking in 
the two rat lines could be associated with their distinct genetic backgrounds (cf. Bell et al. 
2012; McBride et al. 2014). Thus, the innately higher expression levels of Pde4a and Pde4b 
in the NAc shell of P vs NP, but not HAD1 vs LAD1, rats observed in Exp 4 of the present 
study (Table 4) may indicate that the PDE4 system is more involved in EtOH intake by P vs 
HAD1 rats. These findings highlight the need to evaluate target compounds in more than 
one genetic model. With repeated exposure, 1 mg/kg rolipram or 20 mg/kg Ro 20-1724 
consistently reduced alcohol drinking in both rat lines (Fig. 2), suggesting no apparent loss 
in their effectiveness under repeated administration. These results indicate the importance of 
giving repeated treatments in preclinical studies since some effects may not be observed 
with a single treatment or may disappear across consecutive treatments.
PDE inhibition has been reported to reduce alcohol drinking in rodents displaying elevated 
EtOH intake (5–6 g/kg/day) levels (e.g. Hu et al. 2011; Wen et al. 2012). In another study, 
Bell et al. (2014a) reported that repeated injections with the nonselective PDE inhibitor 
ibudilast reduced 2h intake of 15% EtOH in P and HAD1 rats from 2 to 1 g/kg/2hr. 
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Evidence indicates that ibudilast acts as a fairly potent inhibitor of PDE4 (Souness et al. 
1994); however, its lack of specificity precludes the identification of a specific PDE 
subfamily that mediates its alcohol-reducing effects. With regard to PDE4 inhibition, Wen et 
al. (2012) reported that acute rolipram exposure (0.025 and 0.05 mg/kg, s.c.) reduced 5% 
EtOH-reinforced operant responding, and 0.1 and 0.2 mg/kg, s.c. reduced voluntary EtOH 
intake under continuous (5% v/v EtOH) and intermittent (every 3–4 days; 10% EtOH) 2-
bottle choice conditions in Fawn-Hooded rats. In contrast, our findings indicate that a 
similar rolipram dose (0.25 mg/kg, i.p.) did not reduce EtOH intake in P or HAD1 rats (Fig. 
1). Possible explanations for this difference include the route of compound administration, 
the genetic background of the subjects, and operant vs. home-cage drinking parameters. 
Wen et al. (2012) found that four days of exposure to 0.2 mg/kg, rolipram (s.c., 3x per day) 
decreased (~50%) intake of 5% v/v EtOH, under 24h access conditions. Similarly, Hu et al. 
(2011) reported that rolipram (0.25 and 0.50 mg/kg, i.p.) and Ro 20-1724 (10 mg/kg, b.i.d.), 
reduced 24h EtOH drinking of C57BL/6J mice from approximately 6 to 1 g/kg. The success 
of low doses in these two experiments may indicate that rolipram’s short (1–3h) half-life and 
rapid clearance (Krause and Kuhne 1988) require multiple daily exposures to observe 
behavioral changes when examining 24h drinking.
The reductions reported by Hu et al. (2011) exceed those in the present study following 
repeated injections of 1 mg/kg rolipram or 20 mg/kg Ro 20-1724. However, experimental 
differences, including the number and schedule of compound administrations, likely 
contributed to these differences. The present results indicate that the effects on EtOH and 
sucrose drinking may differ between the first test day and the overall test period average (i.e. 
the dose by day interaction; Fig. 2c and Fig. 3a–c). In addition, the current experiments, 
examining the effects of PDE4 inhibitors to alter drinking behaviors, utilized binge-like 
drinking conditions, which may produce different results compared to 24 hr free-choice 
drinking.
The 24h EtOH intake reported by Hu et al. (2011) and Wen et al. (2012) was in the range of 
5–6 g/kg using C57Bl/6J mice and Fawn-Hooded rats, respectively, which is similar to 
levels of 24h EtOH intake reported previously for P and HAD1 rats (Bell et al. 2014b; 
McBride et al. 2014). In the present study, P rats surpassed 80 mg% BEC within the first 30 
min, whereas HAD1 rats displayed an average BEC of 50 mg% after 30 min of access. BEC 
collected from a separate group of HAD1 rats following the 2h drinking sessions exceeded 
100 mg% (data not shown), which is binge-like alcohol drinking (e.g. Bell et al. 2011, 
2014b). Therefore, differences in response to PDE4 inhibitors between the present studies 
and those previously reported may be due to a combination of BECs attained and species/
strain differences.
PDE4 inhibition only had a transient effect on sucrose intake in either rat line (Fig. 3). 
Reductions were no longer present after the first test day. These findings indicate that the 
present reductions in EtOH intake following repeated PDE4 inhibition do not reflect a 
general reduction in the consumption of rewarding fluids.
To assess the effects of repeated exposure with these PDE4 inhibitors on motor impairment, 
LMA tests were conducted at times post-injection coinciding with the time of EtOH or 
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sucrose access (i.e. 60–150 min post-injection). Although other studies with mice (Hu et al. 
2011; Smith 1990) or rats (Wen et al. 2012; Wachtel 1983) reported reduced LMA 
following PDE4 inhibition, the present findings did not observe significant reductions in 
LMA of HAD1 rats. In addition, PDE4 inhibition did not consistently reduce sucrose intake 
suggesting that the reductions in EtOH intake are not attributable to motor-impairment.
Growing evidence supports a role for the anti-immune and anti-inflammatory properties of 
PDE4 inhibition in the treatment of drug (Hutchinson et al. 2007; Narita et al. 2006) and 
alcohol (Fernandez-Lizarbe et al. 2009; Gobejishvili et al. 2008; He and Crews 2008) use 
disorders. CNS evidence from several research arenas suggests that some of the neuro-
protectant qualities of rolipram result from region-specific enhancements in anti-
inflammatory activity and reductions in pro-inflammatory activity (e.g. Schaal et al. 2012; 
Wang et al. 2012).
In the NAc shell, Pde4a expression was higher and Pde4b expression was lower in P rats, 
relative to NP rats. In the CeA, Pde4b expression was also lower relative to NP rats. 
Differences in Pde4 isoform expression between HAD1 and LAD1 rats were only observed 
in the VTA (Table 4). In general, these findings suggest the influence of PDE4 on EtOH 
intake may reside in the extended amygdala of P rats, whereas this influence may be 
localized in the mesolimbic dopamine system of HAD1 rats.
In support of a potential involvement of the neuroinflammatory processes in mediating 
alcohol drinking behavior, micro-infusion into the NAc shell of shRNAs interfering with the 
expression of Il22ra2 significantly reduced EtOH intake by P rats (Fig. 5). IL-22ra2 binds 
and neutralizes IL-22, thus blocking its interactions with cell surface receptor complexes and 
limiting its activity (Kotenko et al. 2001). IL-22 is a member of the IL-10 cytokine 
superfamily that can exert both pro-inflammatory and anti-apoptotic effects (Sanjabi et al. 
2009). Since inhibition of PDE4 will result in the reduction of inflammatory and apoptotic 
responses (Genain et al. 1995; Sekut et al. 1995; Souness et al. 2000; Teixeira et al. 1997; 
Sousa et al. 2010), the findings suggest pro-inflammatory and apoptotic neuro-immune 
system responses to EtOH exposure may be factors contributing to high alcohol drinking by 
the P and HAD1 lines of rats.
Stereotaxic coordinates were verified in a separate group of female P rats prior to the 
microinfusions. In addition, these coordinates have been used successfully in previous 
experiments that employ similar surgical techniques to those in the current study (Engleman 
et al., 2009). Although there may be vector diffusion into the NAc core, the majority of the 
shIl22ra2 vector would likely have infected the shell. Lack of a specific antibody prevented 
the validation of a reduction in IL22ra2 protein levels.
PDE4 inhibition has been reported to inhibit hyperlocomotion associated with 
methamphetamine and morphine (Mori et al. 2000), cocaine sensitization (Janes et al. 2009), 
self-administration (Knapp et al. 1999), and conditioned place preference (Thompson et al. 
2004). It is plausible that PDE4 inhibitors could reduce alcohol and drug use indirectly 
through reducing the DA response to these substances.
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Overall, the current findings support the contribution of neuroimmune signaling to high 
EtOH intake and the potential therapeutic use of PDE4 inhibitors to reduce EtOH intake in 
individuals with AUDs.
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Fig. 1. 
EtOH intake (g/kg) during Exp 1 for EtOH-experienced P and HAD1 rats given 2h limited, 
free-choice access to 15% and 30% v/v EtOH and water, available concurrently. Each 
subject was administered (a) rolipram (0.25, 0.50, and 1.00 mg/kg) or (b) Ro 20-1724 (5, 10, 
and 20 mg/kg), and vehicle (i.p.), in a counterbalanced design, with a different dose 
delivered on each of 4 consecutive days. At 60 min following the injections, rats were given 
2h access to 15% and 30% EtOH. ***, p < 0.001 vs. vehicle.
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Fig. 2. 
EtOH intake (g/kg) during Exp 2 for EtOH-experienced (a, c) P and (b, d) HAD1 rats given 
2h limited, free-choice access to 15% and 30% v/v EtOH and water, available concurrently. 
Each subject was administered rolipram (1 mg/kg; upper panels) or Ro 20-1724 (10 or 20 
mg/kg; lower panels), or vehicle (i.p.), for 5 consecutive test days, using a between-subjects 
design. At 60 min following the injections, rats were given 2h access to 15% and 30% 
EtOH. *, p < 0.05 vs. vehicle; **, p < 0.01 vs. vehicle; ***, p < 0.001 vs. vehicle.
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Fig. 3. 
Sucrose intake (2% w/v; ml/kg) during Exp 2 for (a, c) P and (b, d) HAD1 rats with a history 
of EtOH drinking followed by 4 weeks without EtOH. Each subject was administered 
rolipram (1 mg/kg; upper panels) or Ro 20-1724 (10 or 20 mg/kg; lower panels), or vehicle 
(i.p.), on 5 consecutive test days, using a between-subjects design. At 60 min following the 
injections, rats were given 2h access to sucrose. *, p < 0.05 vs. vehicle; ***, p < 0.001 vs. 
vehicle.
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Fig. 4. 
Cumulative (30 min) distance travelled (cm; upper panels) and rearing counts (lower panels) 
for (a, c) P and (b, d) HAD1 rats during locomotor activity test sessions (Exp 3), following 5 
consecutive days of treatment with 1 mg/kg rolipram, or 20 mg/kg Ro 20-1724, or vehicle 
(i.p.). The 30 min test sessions occurred 6020 mg/kg Ro 20-1724, or vehicle (i.p.). The 30 
min test sessions occurred 60–90 90 or 12020 mg/kg Ro 20-1724, or vehicle (i.p.). The 30 
min test sessions occurred 60–90 150 min following the final injection, and coincided with 
the start of the first and second hrs of consummatory testing during Exp 1 and 2. *, p < 0.05 
vs. vehicle.
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Fig. 5. 
Weekly 15% v/v EtOH (g/kg) and 2% w/v sucrose (ml/kg) per 24h for EtOH-experienced 
female P rats infused with lentiviral vector constructs (#1928 or #1408) expressing Il22ra2 
shRNA (shIl22ra2; black bars) or a scrambled control vector (shScr-; white bars) into the 
NAc shell. Following surgery, rats were given continuous, free-choice access to EtOH (a, c) 
and water, and monitored daily (Mon-Fri) over 620 mg/kg Ro 20-1724, or vehicle (i.p.). The 
30 min test sessions occurred 60–90 7 weeks. Rats were then provided continuous, free-
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choice access to sucrose (b, d) and water, and monitored daily (Mon-Fri) over two additional 
weeks (right side of panels). **, p < 0.01
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Table 1
Dose-dependent 24h intake of water (ml/kg) and food (g/kg), and body weights (g) during Exp 1 by P and 
HAD1 rats across the 4 days of rolipram treatment
Rat Line Dose
(mg/kg)
24h Water
(ml/kg)
24h Food
(g/kg)
Body Weight
(g)
P 0.00 40.0 ± 2.6 42.0 ± 3.1 613.5 ± 12.2
0.25 34.7 ± 3.6 38.8 ± 5.0 613.5 ± 12.2
0.50 41.0 ± 3.5 40.0 ± 2.8 611.9 ± 12.6
1.00 43.3 ± 3.9 38.4 ± 3.2 613.4 ± 12.2
HAD1
0.00 65.8 ± 4.4 55.5 ± 2.0 308.6 ± 7.7
0.25 78.6 ± 4.0 54.8 ± 3.5 307.6 ± 7.6
0.50 77.2 ± 5.7 53.0 ± 2.8 306.7 ± 7.6
1.00 84.5 ± 5.1* 53.3 ± 3.1 310.4 ± 7.4
Within-subjects design (i.p., vehicle [saline + a few drops of Tween 80], or 0.25, 0.50, 1.00 mg/kg rolipram).
*
Indicates that the respective dose differed from vehicle (Dunnett’s t-test, p < 0.05).
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Table 2
Dose-dependent 24h intake of water (ml/kg) and food (g/kg), and body weights (g) during Exp 1 by P and 
HAD1 rats across the 4 days of Ro 20-1724 treatment
Rat Line Dose
(mg/kg)
24h Water
(ml/kg)
24h Food
(g/kg)
Body Weight
(g)
P 0 68.2 ± 8.9 56.1 ± 1.6 435.7 ± 10.4
5 60.8 ± 3.4 53.9 ± 1.3 437.4 ± 10.8
10 63.1 ± 2.6 54.7 ± 1.3 437.6 ± 10.8
20 56.7 ± 3.1 51.1 ± 1.7 437.1 ± 10.3
HAD1
0 104.6 ± 8.3 70.2 ± 3.8 271.7 ± 4.3
5 118.9 ± 7.8 74.9 ± 3.3 273.7 ± 4.2
10 116.9 ± 6.2 74.2 ± 3.2 271.0 ± 3.8
20 113.7 ± 8.6 63.9 ± 3.9 273.4 ± 4.1
Within-subjects design (i.p., vehicle [saline + a few drops of Tween 80], or 5, 10, 20 mg/kg Ro 20-1724).
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Table 3
Average 24h water and food intake, and body weight during Exp 2, by alcohol-drinking P and HAD1 rats 
across the 5-day test of rolipram or Ro-201724 administration.
Rat Line Treatment-Dose
(mg/kg)
24h Water
(ml/kg)
24h Food
(g/kg)
Body Weight
(g)
P
RPM 0 33.2 ± 1.7 37.3 ± 1.1 635.2 ± 16.4
RPM 1 48.0 ± 2.1* 39.4 ± 0.5 604.5 ± 10.1
RO 0 66.9 ± 2.5 53.3 ± 1.9 465.8 ± 13.2
RO 10 57.1 ± 1.5 48.3 ± 2.3 459.5 ± 14.0
RO 20 54.0 ± 5.8* 36.6 ± 1.5* 522.2 ± 13.1*
HAD1
RPM 0 69.4 ± 5.0 62.6 ± 2.3 315.5 ± 6.7
RPM 1 81.9 ± 5.4 63.6 ± 3.4 311.2 ± 13.7
RO 0 90.4 ± 5.5 64.1 ± 1.5 297.8 ± 4.1
RO 20 131.8 ± 16.0* 62.7 ± 1.5 277.5 ± 8.3*
Animals were given 1 mg/kg rolipram (RPM) or 10 or 20 mg/kg Ro 20-1724 (RO) (i.p., vehicle [saline + a few drops of Tween80], using a 
between-subjects design.
*
Indicates that the respective dose differed from vehicle (p < 0.05).
Psychopharmacology (Berl). Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Franklin et al. Page 24
Ta
bl
e 
4
Ex
pr
es
sio
n 
le
ve
ls 
of
 g
en
es
 e
nc
od
in
g 
fo
r P
D
E4
A
 a
nd
 P
D
E4
B 
in
 th
e 
nu
cl
eu
s a
cc
um
be
ns
 sh
el
l, 
ce
nt
ra
l n
uc
le
us
 o
f t
he
 a
m
yg
da
la
, a
nd
 v
en
tra
l t
eg
m
en
ta
l a
re
a 
o
f E
tO
H
-n
aï
ve
 P
 v
s. 
N
P 
an
d 
H
A
D
1 
vs
. L
A
D
1 
ra
ts.
P 
vs
 N
P
H
A
D
1 
vs
 L
A
D
1
G
en
e S
ym
N
uc
le
us
 A
cc
um
be
ns
 S
he
ll
Fo
ld
-C
ha
ng
e
P-
va
lu
e*
Fo
ld
-C
ha
ng
e
P-
va
lu
e*
pd
e4
a
ph
os
ph
od
ie
ste
ra
se
 4
A
1.
24
0.
00
1
1.
07
0.
46
1
pd
e4
b1
ph
os
ph
od
ie
ste
ra
se
 4
B
−
1.
15
0.
11
7
1.
09
0.
45
4
pd
e4
b2
ph
os
ph
od
ie
ste
ra
se
 4
B
−
1.
20
0.
00
6
−
1.
05
0.
21
5
P 
vs
 N
P
H
A
D
1 
vs
 - 
LA
D
1
Sy
m
C
en
tr
al
 A
m
yg
da
la
Fo
ld
-C
ha
ng
e
P-
va
lu
e*
Fo
ld
 C
ha
ng
e
P-
va
lu
e*
pd
e4
a
ph
os
ph
od
ie
ste
ra
se
 4
A
−
1.
06
0.
22
7
−
1.
04
0.
51
8
pd
e4
b1
ph
os
ph
od
ie
ste
ra
se
 4
B
−
1.
17
0.
02
3
1.
03
0.
56
3
pd
e4
b2
ph
os
ph
od
ie
ste
ra
se
 4
B
−
1.
08
0.
07
2
−
1.
05
0.
57
4
P 
vs
 N
P
H
A
D
1 
vs
 L
A
D
1
Sy
m
V
en
tr
al
 T
eg
m
en
ta
l A
re
a
Fo
ld
-C
ha
ng
e
P-
va
lu
e*
Fo
ld
-C
ha
ng
e
P-
va
lu
e*
pd
e4
a
ph
os
ph
od
ie
ste
ra
se
 4
A
1.
03
0.
55
5
−
1.
10
0.
30
3
pd
e4
b1
ph
os
ph
od
ie
ste
ra
se
 4
B
−
1.
02
0.
46
9
−
1.
01
0.
84
6
pd
e4
b2
ph
os
ph
od
ie
ste
ra
se
 4
B
1.
02
0.
57
3
1.
10
0.
02
0
pd
e4
a,
 A
ffy
 ID
: 1
36
86
70
_a
_a
t; 
pd
e4
b1
, A
ffy
 ID
: 1
36
90
44
_a
_a
t; 
pd
e4
b2
, A
ffy
 ID
: 1
37
41
57
_a
t; 
13
68
75
0_
a_
at
;
*
p 
< 
0.
05
; U
nc
or
re
ct
ed
 fo
r m
ul
tip
le
 co
m
pa
ris
on
s. 
Pa
re
nt
he
siz
ed
 n
um
be
rs
 in
di
ca
te
 in
di
vi
du
al
 p
ro
be
 se
ts.
 P
 (A
lco
ho
l-p
ref
err
ing
); 
NP
 (A
lco
ho
l N
on
pre
fer
rin
g);
 H
AD
1 (
Hi
gh
 A
lco
ho
l D
rin
kin
g);
 L
AD
1 (
Lo
w 
A
lc
oh
ol
 D
rin
ki
ng
) r
ats
.
Psychopharmacology (Berl). Author manuscript; available in PMC 2016 July 01.
